#	Pagina
attuale pagina	/open-h2020/projects/205059/index.html
-1	/open-h2020/projects/209051/index.html
-2	/open-h2020/projects/213463/index.html
-3	/open-h2020/projects/213506/index.html
-4	/open-h2020/projects/194070/index.html
-5	/open-consip/fornitori/2014/profilo-04050650722/index.html
-6	/open-h2020/per-topic/interfering/list/index.html
-7	/open-consip/fornitori/2015/profilo-02067210696/index.html
-8	/open-consip/fornitori/2014/profilo-11433481006/index.html
-9	/open-consip/fornitori/2014/profilo-04130490966/index.html
-10	/open-consip/fornitori/2015/profilo-11433481006/index.html

Opendata, web and dolomites

CardAPcells

Cell therapy for patients with chronic heart failure with proprietary cardiac-derived cells (CardAP cells) – “From the Heart to the Heart”

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CardAPcells project word cloud

Explore the words cloud of the CardAPcells project. It provides you a very rough idea of what is the project "CardAPcells" about.

suffer cure worldwide morbidity efficacy finalised heart fulfilment mio donor approval people specialized models gmp introduction acquired threatening preliminary preparation cardiomyopathy multicenter usually spin therapies safety eacute disease bridge advantages stress medicine off suffering regulatory severe exclusive achievements 140 area market atmp fulfil financial preparations cardap facilities transferred hospital university 45 insufficiency financing stromal therapeutic clinical cellserve criteria hearts stem life perform exemption therapy mortality charit except commercial cells projected cardiac die trial curative patients equity rare artificial limited business calculations completely solution atmps manufacturing chronic competitors license cell germany plan progressive regulation 22

Project "CardAPcells" data sheet

The following table provides information about the project.

Coordinator	CELLSERVE GMBH Organization address address: CHARITEPLATZ 1 city: BERLIN postcode: 10117 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.cellserve.de/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-07-01 to 2016-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CELLSERVE GMBH CELLSERVE GMBH Organization address address: CHARITEPLATZ 1 city: BERLIN postcode: 10117 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	coordinator	50˙000.00

Map

Project objective

Chronic heart failure is a life-threatening disease usually without cure and a leading cause of morbidity and mortality. In Germany 45 000 patients (projected to EU: about 140 000) die every year from progressive chronic cardiac insufficiency. There is no curative therapeutic solution, except very rare donor hearts and artificial hearts as bridge devices. Researchers at the Charité - University Medicine, have identified unique cardiac-specific stromal cells (CardAP cells) with strong efficacy in cardiac stress models. CardAP cells are specialized heart-derived cells with key advantages in safety and efficacy. CardAP cells fulfil all criteria for cardiac cell therapy and cell product manufacturing has been transferred to GMP facilities. CellServe, a Charité spin off, will develop the CardAP cells for therapy of patients suffering from severe life-threatening cardiomyopathy. CellServe has acquired an exclusive license of this technology and will perform a clinical phase I/II study for patients with chronic cardiomyopathy. The technology of CellServe is completely distinct from all competitors, using specialized stromal heart cells and not stem cells.

CellServe has an experienced management in cell-based therapies area to develop and market ATMP products. It will apply for a so-called hospital exemption regulation, a limited preliminary approval, for early market introduction directly after the clinical study. Commercial potential: Worldwide 22 Mio people suffer from chronic cardiac insufficiency. â€¨ In Phase 1 a business plan for the CardAP cell product will be generated including financial calculations and the preparations for the clinical study will be finalised.â€¨ Achievements Phase 2:â€¨• Phase I/II clinical trialâ€¨• Approval for Hospital Exemption for ATMPsâ€¨• Preparation of a multicenter clinical trialâ€¨• Fulfilment of all regulatory requirements to perform a phase III clinical studyâ€¨• Equity financing

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDAPCELLS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDAPCELLS" are provided by the European Opendata Portal: CORDIS opendata.